Abstract: The invention provides hisS polypeptides and DNA (RNA) encoding hisS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hisS polypeptides to screen for antibacterial compounds.
Type:
Grant
Filed:
August 6, 1997
Date of Patent:
August 18, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Daniel Robert Gentry, Rebecca Claire Greenwood, Elizabeth Jane Lawlor
Abstract: Solid phase combinatorial synthesis is carried out in a multi-reactor synthesizer comprising an array of separate reactor cells containing a solid reaction support medium. Subsets of reactor cells are interconnected with one another in a desired pattern, and, in a first reaction step, reagents are circulated through the subsets. After the first reaction step is completed, the reactor cells are rearranged into a new configuration of subsets, and the same, or other, reagents are circulated through the new subsets. The process can be repeated to produce large numbers of compounds differing from one another.
Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
August 4, 1998
Assignee:
SmithKline Beecham p.l.c.
Inventors:
John Edward Hodgson, Elizabeth Jane Lawlor
Abstract: Human ELF3 polypeptides and DNA (RNA) encoding such ELF3 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such ELF3 for the diagnosis and treatment of cancers, in particular prostate, breast, lung or other epithelial tumors, among others.
Type:
Grant
Filed:
November 15, 1996
Date of Patent:
August 4, 1998
Assignees:
SmithKline Beecham Corporation, Monash University
Inventors:
Ismail Kola, Martin J. Tymms, Christine Debouck
Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
August 4, 1998
Assignee:
Smithkline Beecham p.l.c.
Inventors:
John Edward Hodgson, Elizabeth Jane Lawlor
Abstract: This invention relates to human galactokinase and the identification of galactokinase mutations, a missense and nonsense, as well as isolated nucleic acids encoding same, recombinant host cell transformed with DNA encoding such proteins and to uses of the expressed proteins and nucleic acid sequences in therapeutic and diagnostic applications.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
August 4, 1998
Assignees:
SmithKline Beecham Corporation, The Trustees of the University of Pennsylvania
Inventors:
Derk Jon Bergsma, Dwight Edward Stambolian, Steven M. Ruben, Craig A. Rosen
Abstract: lep polypeptides and DNA (RNA) encoding such lep and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such lep for the treatment of infection, particularly bacterial infections. Antagonists against such lep and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of lep nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding leader peptidase and for detecting the polypeptide in a host.
Abstract: Compounds of formula (I), or pharmaceutically acceptable salts thereof are provided: ##STR1## in which X.sub.1 --(CH.sub.2).sub.x --X.sub.2 forms a 5-7 membered ring wherein:X.sub.1 is O or S;X.sub.2 is O, S or NR wherein R is hydrogen;x is 1, 2 or 3;R.sub.1 is hydrogen, amino, halo, C.sub.1-6 alkyl, hydroxy or C.sub.1-6 alkoxy;R.sub.2 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, nitro, amino or C.sub.1-6 alkylthio;R.sub.3 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or amino;R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6 alkyl;Y is NH;Z is of sub-formula (a): ##STR2## wherein --(CH.sub.2).sub.n.sup.1 is attached at carbon; andn.sup.1 is 0, 1, 2, 3 or 4;q is 0, 1, 2 or 3;R.sub.a is (CH.sub.2).sub.n.sup.2 --R.sub.7 wherein n.sup.2 is 2 or 3 and R.sub.7 is selected from cyano, hydroxyl, C.sub.1-6 alkoxy, phenoxy, C(O)C.sub.1-6 alkyl, COC.sub.6 H.sub.5, --CONR.sub.8 R.sub.9, NR.sub.8 COR.sub.9, SO.sub.2 NR.sub.8 R.sub.9 or NR.sub.8 SO.sub.2 R.sub.9 whereinR.sub.8 and R.sub.
Type:
Grant
Filed:
December 20, 1996
Date of Patent:
July 28, 1998
Assignee:
SmithKline Beecham p.l.c.
Inventors:
Francis David King, Laramie Mary Gaster, Keith Raymond Mulholland
Abstract: The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.
Abstract: A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
Inventors:
Michael Joseph Browne, Peter Ronald Young, Allan Richard Shatzman, Kay Elizabeth Murphy, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard
Abstract: The present invention relates to treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs and other altered antibodies such as Fabs, chimeric, human and humanized antibodies that do not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor.
Type:
Grant
Filed:
June 21, 1996
Date of Patent:
July 21, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Edward Robert Appelbaum, Richard Murray Cook
Abstract: The invention provides FabH polypeptides and DNA (RNA) encoding such FabH and a procedure for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such FabH for the treatment of infection, particularly bacterial infections. Antagonists against such FabH and their use as a therapeutic to treat infections, particularly bacterial infections are also provided. Further provided are diagnostic assays for detecting diseases related to the presence of FabH nucleic acid sequences and the polypeptides in a host. Also provided are diagnostic assays for detecting polynucleotides encoding novel Fab family proteins and for detecting such polypeptides in a host.
Type:
Grant
Filed:
August 25, 1997
Date of Patent:
July 21, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Daniel Robert Gentry, John Timothy Lonsdale, David John Payne, Stewart Campbell Pearson
Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
Type:
Grant
Filed:
May 31, 1994
Date of Patent:
July 21, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, James E. Strickler, Peter R. Young
Abstract: Nucleic acid molecules encoding a human B cell surface molecule are provided. Polypeptides and antibodies which bind to these polypeptides are also provided. In addition, methods of detecting mutated forms of the molecule are provided.
Abstract: Novel cyclohexane derivatives of Formula (I) ##STR1## are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; they are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV and are therefore useful in the treatment of disease states in need of mediation or inhibition thereof.
Abstract: The invention relates to Arginase II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
Type:
Grant
Filed:
August 20, 1996
Date of Patent:
July 14, 1998
Assignees:
SmithKline Beecham Corporation, Human Genome Sciences Inc.
Abstract: This invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease scates mediated by the chemokine, Interleukin-8 (IL-8). In particular, this invention relates to the novel compounds of Formula (Ia) and their use in treating chemokine mediated diseases wherein the chemokine binds to an IL-8 a or b receptor. Compounds of Formula (Ia) are represented by the structure: ##STR1## wherein interalia, X is oxygen or sulfur;Rb is NR.sub.6 R.sub.7, alkcyl, aryl, arylC.sub.1-4 alkyl, aryl C.sub.2-4 alkenyl, heteroaryl, heteroarylC.sub.1-4 alkyl, heteroarylC.sub.2-4 alkenyl, heterocyclic or heterocyclic C.sub.1-4 alkyl, or a heterocyclic C.sub.2-4 alkenyl moiety, camphor, all of which may be optionally substituted;R.sub.1 is independently selected from hydrogen; halogen; nitro; cyano; C.sub.1-10 alkyl; halosubstituted C.sub.1-10 alkyl; C.sub.2-10 alkoxy; halosubstituted C.sub.1-10 alkoxy; azide; (CR.sub.8 R.sub.8)q S(O).sub.t R.sub.4 ; hydroxy; hydroxy substituted C.sub.
Type:
Grant
Filed:
August 21, 1996
Date of Patent:
July 14, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Katherine Louisa Widdowson, Daniel Frank Veber, Anthony Joseph Jurewicz, Robert Philip Hertzberg, Melvin Clarence Rutledge, Jr.
Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
July 7, 1998
Assignee:
SmithKline Beecham p.l.c.
Inventors:
John Edward Hodgson, Elizabeth Jane Lawlor
Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
July 7, 1998
Assignee:
Smithkline Beecham p.l.c.
Inventors:
John Edward Hodgson, Elizabeth Jane Lawlor